All In Biotech

Drug Trial Radar · NCT01717118

Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico

Last checked: Nov 19, 2026Latest source record: Aug 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,000

Actual

Start

Nov 2009

Primary completion

Feb 2015

Study completion Aug 2018

Sponsor

Lead sponsor
Instituto Nacional de Salud Publica, MexicoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Secretaria de Salud, Mexico
First posted
Oct 30, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Other
Who can join
Female only, from 9 years, up to 24 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In September 2009 the National Vaccination Council approved the policy for anti-HPV vaccination in 9-year-old girls with an extended scheme of 0, 6, and 60 months, under the following justification: * Antibody induction due to the vaccine is greater than that produced by natural exposure to the virus * Immune response in girls 9 to 11 years of age is similar to the response obtained after three doses in women 16 to 26 years of age * The third dose will be administered at the time when maximum protection is required, near the onset of sexual activity Thus the National Institute of Public Health was commissioned to monitor anti-HPV antibody levels in women who received the anti-HPV vaccine to determine non-inferiority of the extended scheme in 9-year-old girls compared with the traditional scheme of 3 doses in women 18 to 24 years of age. To this end, a sentinel cohort will be formed to evaluate immunogenicity levels in 3 age groups, and stratified by vaccine type. The hypothesis is that in 9-year-old girls who are administered the amplified HPV vaccination scheme (0-6-60) show immunogenicity levels that are not lower than those of adult women who have been administered the traditional scheme (0-1/2-6). The main objectives are to monitor the levels of immunity induced by vaccination against HPV with two vaccination schemes with the quadrivalent vaccine: Traditional Extended (0-6-60 months) and traditional (0-2-6); Monitoring levels of immunity induced by vaccination against HPV with three vaccine schemes with bivalent vaccine: Extended (0-6-60 months), traditional (0-1-6) and two doses (0- 6); as well as evaluating the interchangeability of the bivalent and quadrivalent vaccines in the third dose of extended scheme. The study design is to create a sentinel cohort of women vaccinated against HPV in the following comparison groups: * Women of nine years with extended vaccination scheme with three doses of quadrivalent vaccine (0-6-60) * Women of nine years with extended vaccination scheme with two doses of the quadrivalent vaccine and the third dose with bivalent (0-6-60) * Women of nine years with traditional vaccination scheme with the quadrivalent HPV vaccine (0-2-6) * Women between 18 and 24 years with traditional vaccination scheme with the quadrivalent HPV vaccine (0-2-6) * Women of nine years with extended vaccination scheme with three doses of bivalent vaccine (0-6-60) * Women of nine years with extended vaccination scheme with two doses of bivalent vaccine and the third tetravalent dose * Women of nine years with two vaccine doses scheme with the bivalent HPV vaccine (0-6) * Women of nine years with traditional vaccination scheme with bivalent HPV vaccine (0-1-6) * Women between 18 and 24 years with traditional vaccination scheme with bivalent HPV vaccine (0-1-6) * To monitoring HPV infections, at month 61 of follow-up, a group of 400 women aged 14-15 years, who have not been vaccinated against HPV, will be invited , in order to make the monitoring of occurrence of HPV infections in urine per month 61, 72, 96 and 120 post dose 0 in vaccinated groups

Conditions

  • Healthy

Interventions

  • Bivalent VaccinesBiological

  • Tetravalent VaccineBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To monitor immunogenicity levels induced by anti/HPV vaccine in traditional squemeTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centro Médico Cuauhtemoc

    Cuernavaca, Morelos, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.